Post-earnings recap
Reported
Wed, Nov 7, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Celldex Therapeutics reported a narrower-than-expected loss per share, which led to a positive stock reaction, rising 3.44%. The company did not provide revenue figures or future guidance, leaving some uncertainty for investors. However, management's positive tone regarding clinical progress may have contributed to the stock's increase.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.04 | N/A | +64.40% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the quarter's performance, particularly regarding EPS. They emphasized ongoing efforts in clinical development.
We are pleased with our progress this quarter.
Our focus remains on advancing our clinical programs.